JP2022507218A5 - - Google Patents
Info
- Publication number
- JP2022507218A5 JP2022507218A5 JP2021525682A JP2021525682A JP2022507218A5 JP 2022507218 A5 JP2022507218 A5 JP 2022507218A5 JP 2021525682 A JP2021525682 A JP 2021525682A JP 2021525682 A JP2021525682 A JP 2021525682A JP 2022507218 A5 JP2022507218 A5 JP 2022507218A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- inhibitor
- pharmaceutical product
- bfl
- cdk9
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862767215P | 2018-11-14 | 2018-11-14 | |
| US62/767,215 | 2018-11-14 | ||
| PCT/EP2019/081145 WO2020099470A1 (en) | 2018-11-14 | 2019-11-13 | Methods of treating cancer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022507218A JP2022507218A (ja) | 2022-01-18 |
| JP2022507218A5 true JP2022507218A5 (enExample) | 2022-11-18 |
Family
ID=68583377
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021525682A Pending JP2022507218A (ja) | 2018-11-14 | 2019-11-13 | 癌を治療する方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20220008392A1 (enExample) |
| EP (1) | EP3881075A1 (enExample) |
| JP (1) | JP2022507218A (enExample) |
| CN (1) | CN112997078A (enExample) |
| TW (2) | TWI810397B (enExample) |
| WO (1) | WO2020099470A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7900421B2 (ja) | 2021-06-11 | 2026-08-04 | ギリアード サイエンシーズ， インコーポレイテッド | Ｍｃｌ－１阻害剤と抗がん剤との組み合わせ |
| TWI861509B (zh) | 2021-06-11 | 2024-11-11 | 美商基利科學股份有限公司 | Mcl-1抑制劑與抗體藥物接合物之組合 |
| IT202400003478A1 (it) * | 2024-02-19 | 2025-08-19 | Sbarro Health Res Organization Inc | Cdk9 per uso nella determinazione della reattivita' di un tumore a un chemioterapico o per uso nel trattamento del cancro |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2016252609B2 (en) * | 2015-04-20 | 2022-06-30 | Sumitomo Pharma Oncology, Inc. | Predicting response to alvocidib by mitochondrial profiling |
| TR201909286T4 (tr) | 2015-06-29 | 2019-07-22 | Astrazeneca Ab | CDK9 inhibitörleri olarak polisiklik amid türevleri. |
| CR20180499A (es) | 2016-04-22 | 2019-01-25 | Astrazeneca Ab | Inhibidores de mcl1 macrocicliclos para tratar el cancer |
-
2019
- 2019-11-05 TW TW108140085A patent/TWI810397B/zh not_active IP Right Cessation
- 2019-11-05 TW TW112104478A patent/TW202344250A/zh unknown
- 2019-11-13 CN CN201980074261.9A patent/CN112997078A/zh active Pending
- 2019-11-13 EP EP19805211.0A patent/EP3881075A1/en not_active Withdrawn
- 2019-11-13 US US17/293,155 patent/US20220008392A1/en not_active Abandoned
- 2019-11-13 JP JP2021525682A patent/JP2022507218A/ja active Pending
- 2019-11-13 WO PCT/EP2019/081145 patent/WO2020099470A1/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Gupta et al. | Onychomycosis: a review | |
| Fischer et al. | The risk of hand-foot skin reaction to axitinib, a novel VEGF inhibitor: a systematic review of literature and meta-analysis | |
| Li et al. | Dihydroartemisinin selectively inhibits PDGFRα-positive ovarian cancer growth and metastasis through inducing degradation of PDGFRα protein | |
| JP6441303B2 (ja) | Ｃ型肝炎を治療するための２種の抗ウイルス剤の併用 | |
| US20160032404A1 (en) | Biomarkers for predicting response of dlbcl to treatment with a btk inhibitor | |
| KR20160066554A (ko) | 브루톤 타이로신 키나제 억제제 및 면역요법을 이용한 치료 | |
| JP2016513640A5 (enExample) | ||
| JP2023533464A5 (enExample) | ||
| KR20160006668A (ko) | 브루톤 티로신 키나제 억제제와 cyp3a4 억제제의 배합물 | |
| JP2016034978A5 (enExample) | ||
| Sun et al. | Nitidine chloride inhibits ovarian cancer cell migration and invasion by suppressing MMP-2/9 production via the ERK signaling pathway | |
| JP2019532047A5 (enExample) | ||
| Paudel et al. | In vitro anti-cancer activity of a polyherbal preparation, VEDICINALS® 9, against A549 human lung adenocarcinoma cells | |
| CN109908353A (zh) | 用于治疗hcv患者的直接作用的抗病毒剂和利巴韦林的组合 | |
| Abaza et al. | Valproic acid, an anti-epileptic drug and a histone deacetylase inhibitor, in combination with proteasome inhibitors exerts antiproliferative, pro-apoptotic and chemosensitizing effects in human colorectal cancer cells: underlying molecular mechanisms | |
| Baffoe et al. | Disulfiram‐loaded immediate and extended release vaginal tablets for the localised treatment of cervical cancer | |
| JP2021514975A5 (enExample) | ||
| JP2023531675A5 (enExample) | ||
| WO2018148598A1 (en) | Compositions for treating breast cancer | |
| RU2020120876A (ru) | Фармацевтическая композиция, содержащая антагонист минералокортикоидных рецепторов, и ее применение | |
| JP2019530711A5 (enExample) | ||
| O’Grady et al. | Liver cancer (hepatocellular carcinoma) | |
| Chap et al. | Treatment of cutaneous iatrogenic Kaposi sarcoma with topical timolol. | |
| Hamzelou et al. | Superficial plantar angiomyxoma in a young man. | |
| Xu et al. | Scutellarin regulates MAPK/ERK signalling in nasopharyngeal cancer via the apoptotic and ROS induced DNA damage |